EMILY.AI

Emily.AI is a medical device powered by Artificial Intelligence (AI) developed to enhance the treatment, monitoring, and support of patients with respiratory conditions.

An AI developed by leaders in the clinical field and AI, allows oxygen to be individualized to the patient’s needs, and the platform (app and control panel) allows medical supervision of all connected patients.

Among our collaborations are pharmaceutical companies, oxygen production companies, and medical device manufacturers, as well as private and public hospitals, banks, and agreements with the main respiratory patient associations and first-level medical device companies.

• An AI developed by industry leaders with PhDs in the field at Harvard and MIT, with Fulbright and la Caixa grants, who work closely with researchers with National Research Awards.
• A control panel that allows clinicians to monitor all patients in an aggregated manner in real time and modify the oxygen titration remotely.
• A device in the clinical validation and certification phase (ISO 27001, ENS, ISO 13485, HIPAA/GDPR, among others) weighing less than 400 grams, compatible with any oxygen source that can manage large volumes of oxygen (for acute cases).
• We have preliminary results in the Intermediate Care Unit, maintaining an average of 94% in optimal SpO2 in acute patients, reducing nursing time by 25% and oxygen consumption by 25% per patient/day.